Cascinu Stefano Professore OrdinarioMedicinaMED/06

Biografia

Pubblicazioni

Biografia

Posizioni Universitarie:

Professore Associato di Oncologia Medica, (1998-2002)  

Facolta di Medicina e Chirurgia Università degli Studi di Messina        

Professore Associato di Oncologia Medica, (2002-2006)

Professore Ordinario di Oncologia Medica (2006-2105)

Direttore Scuola di Specializzazione in Oncologia medica (2010-2015)

Coordinatore Dottorato di Ricerca Oncologia

Presidente Corso di Laurea Infermieristica Polo di Pesaro (2011-2014)

Facoltà di Medicina e Chirurgia, Università Politecnica delle Marche

Professore Ordinario di Oncologia Medica (2015-2019) Università di Modena e Reggio Emilia

Consigliere del CdA Università di Modena e Reggio Emilia (2016-2019)

Professore ordinario di Oncologia Medica (2019-

Università Vita-Salute, San Raffaele Milano.

 

Posizioni Ospedaliere:

Assistente Medico, U.O. Oncologia Medica, Azienda Ospedaliera di Pesaro (PU) (1990-1994)

Aiuto Medico, Clinica di Oncologia Medica, Ospedali Riuniti di Ancona, Università degli Studi di Ancona (1994-1997)

House staff, Moses Division of Medical Oncology, Montefiore Hospital, New York (NY) USA (1995)

Responsabile, Sezione Terapie innovative in Oncologia, Istituto di Oncologia e Ricerca sui Tumori, Policlinico di Messina (1998-2000)

Direttore, U.O. Oncologia Medica, Azienda Ospedaliera di Parma, Università degli Studi di Parma (2000-2002)

Direttore, Clinica di Oncologia Medica, A.O. Ospedali Riuniti di Ancona, Università Politecnica delle Marche (2002-2015)

Direttore, Oncologia Medica. Policlinico di Modena (2015-2019)

Direttore, Dipartimento integrato di Oncologia e Ematologia. Policlinico di Modena (2016-2019).

Direttore, Oncologia Medica, IRCCS- Ospedale San       Raffaele (2019-)

Società Scientifiche:

Associazione Italiana di Oncologia Medica (AIOM)

Consigliere Nazionale: AIOM (1995-1999)

Segretario Nazionale: AIOM (2005-2007)

Presidente Nazionale: AIOM (2011-2014)

European Society of Medical Oncology (ESMO)

Membro dell’Educational Committee

Coordinatore linee guida europee tumori del pancreas;

Revisore linee guida tumori del tratto gastrointestinale

Faculty Gastrointestinal tumors

American Society of Clinical Oncology                                                            

Incarichi istituzionali:        

Membro Commissione Oncologica Nazionale (2006-2008)

Membro, Commissione Reti cliniche oncologiche AGENAS (2013-2014)

Esperto, EMA (2014-)

Presidente, Comitato Etico IRCCS Istituto tumori e Area Vasta della Romagna (2011-)

 

Incarichi scientifici:

Comitato tecnico-scientifico AIRC

Comitato tecnico-scientifico “Fondazione Berlucchi”

Comitato tecnico-scientifico IRCCS Istituto Tumori    della Romagna (2015-)


 

Pubblicazioni

Prof. Stefano Cascinu

Elenco pubblicazioni

  1. Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P.Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier). Cancer Manag Res. 2019 Apr 26;11:3631-3642.
  2. Losi L, Bertolini F, Guaitoli G, Fabbiani L, Banchelli F, Ambrosini-Spaltro A, Botticelli L, Scurani L, Baldessari C, Barbieri F, Cascinu S, Maiorana A.Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. Int J Oncol. 2019 Nov;55(5):1157-1164. doi: 10.3892/ijo.2019.4883. Epub 2019 Sep 20.
  3. Weide B, Eigentler T, Catania C, Ascierto PA, Cascinu S, Becker JC, Hauschild A, Romanini A, Danielli R, Dummer R, Trefzer U, Elia G, Neri D, Garbe C. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunol Immunother. 2019 Sep;68(9):1547-1559. doi: 10.1007/s00262-019-02383-z.
  4. Salati M, Orsi G, Smyth E, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S. Gastric cancer: Translating novels concepts into clinical practice. Cancer Treat Rev. 2019 Epub 2019 Aug 14.
  5. Toss A, Venturelli M, Sperduti I, Molinaro E, Isca C, Barbieri E, Piacentini F, Omarini C, Cortesi L, Cascinu S, Moscetti L.First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. Clin Breast Cancer. 2019 Jul 24. pii: S1526-8209(19)30418-5. doi: 10.1016/j.clbc.2019.06.011. [Epub ahead of print]
  6. Vitale MG, Baldessari C, Milella M, Buti S, Militello AM, Di Girolamo S, Fornarini G, Perri G, Basso U, Maruzzo M, Porta C, Cosmai L, Pipitone S, Cerma K, Cascinu S, Sabbatini R  Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.Clin Genitourin Cancer. 2019 Oct;17(5):e903-e908. doi: 10.1016/j.clgc.2019.06.009. Epub 2019 Jul 8
  7. Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini A. ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers (Basel). 2019 Jul 20;11(7). pii: E1023. doi: 10.3390/cancers11071023.
  8. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. Eur J Cancer. 2019 Sep;118:121-130. doi: 10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19.
  9. Salati M, Caputo F, Cunningham D, Marcheselli L, Spallanzani A, Rimini M, Gelsomino F, Reggiani-Bonetti L, Andrikou K, Rovinelli F, Smyth E, Baratelli C, Kouvelakis K, Kalaitzaki R, Gillbanks A, Michalarea V, Cascinu S, Braconi C. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.Eur J Cancer. 2019 Aug;117:84-90. doi: 10.1016/j.ejca.2019.05.030. Epub 2019 Jul 2.
  10. Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P. Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier). Cancer Manag Res. 2019 Apr 26;11:3631-3642. doi: 10.2147/CMAR.S197349.
  11. Guaitoli G, Baldessari C, Bertolini F, Tomasello C, Cascinu S, Barbieri F.Are we ready to describe response or progression to immunotherapy in lung cancer? Crit Rev Oncol Hematol. 2019 Jun;138:112-119. doi: 10.1016/j.critrevonc.2019.04.002. Epub 2019 Apr 4. Revie
  12. Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S, Murrone A, Bianchi F, Amantini C, Giulietti M, Ricci G, Principato G, Santoni G, Berardi R, Cascinu S. Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS One. 2019 May 2;14(5):e0215990. doi: 10.1371/journal.pone.0215990. eCollection 2019.
  13. Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M. Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clin Cancer Res. 2019 Jul 1;25(13):3954-3961. doi: 10.1158/1078-0432.CCR-19-0311. Epub 2019 Apr 9.
  14. De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G, Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A, Ercolani G, Santini D, Frassineti GL, Faloppi L, Scartozzi M, Cascinu S, Casadei-Gardini A.  Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.Int J Mol Sci. 2019 Mar 26;20(6). pii: E1503. doi: 10.3390/ijms20061503.
  15. Negri F, De Giorgi A, Gilli A, Azzoni C, Bottarelli L, Gnetti L, Goldoni M, Manotti L, Sgargi P, Michiara M, Leonardi F, Rindi G, Cascinu S, Silini EM. Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series. Sci Rep. 2019 Mar 6;9(1):3668. doi: 10.1038/s41598-019-40096-6.
  16. Cascinu S, Poli D, Zaniboni A, Lonardi S, Labianca R, Sobrero A, Rosati G, Di Bartolomeo M, Scartozzi M, Zagonel V, Pella N, Banzi M, Torri V. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. Eur J Cancer. 2019 Apr;111:1-7. doi: 10.1016/j.ejca.2019.01.020. Epub 2019 Feb 21.
  17. Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep. 2019 Feb 11;9(1):1788. doi:
  18. Toss A, Venturelli M, Molinaro E, Pipitone S, Barbieri E, Marchi I, Tenedini E, Artuso L, Castellano S, Marino M, Tagliafico E, Razzaboni E, De Matteis E, Cascinu S, Cortesi L. Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. Cancers (Basel). 2019 Feb 7;11(2).
  19. Omarini C, Bettelli S, Caprera C, Manfredini S, Barbolini M, Moscetti L, Isca C, Toss A, Barbieri E, Cortesi L, Kaleci S, Maiorana A, Tazzioli G, Cascinu S, Piacentini F. Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. J Cancer Res Clin Oncol. 2019 Jan 2.
  20. Salati M, Valeri N, Spallanzani A, Braconi C, Cascinu S. Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. Eur J Surg Oncol. 2018 Nov 10. pii: S0748-7983(18)31997-8.
  21. Gelsomino F, Spallanzani A, Orsi G, Caputo F, Santini C, Cascinu S. To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. Crit Rev Oncol Hematol. 2018 Dec;132:154-160. Epub 2018 Oct 11.
  22. Malavasi VL, Fantecchi E, Gianolio L, Pesce F, Longo G, Marietta M, Cascinu S, Lip GYH, Boriani G. Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. Eur J Intern Med. 2018 Oct 29. pii: S0953-6205(18)30405-9. doi: 10.1016/j.ejim.2018.10.012. [Epub ahead of print]
  23. Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini M, Riggi L, Cascinu S. Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018 Nov;18(11):1069-1076. doi: 10.1080/14737140.2018.1524297. Epub 2018 Sep 21.
  24. Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, André T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.Oncologist. 2018 Sep 6. pii: the oncologist.2018-0072. doi: 10.1634/theoncologist.2018-0072. [Epub ahead of print]
  25. Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, Wolthuis A, Daniels IR, Hompes R, Penna M, Fürst A, Papamichael D, Desai AM, Cascinu S, Gèrard JP, Myint AS, Lemmens VEPP, Berho M, Lawler M, De Liguori Carino N, Potenti F, Nanni O, Altini M, Beets G, Rutten H, Winchester D, Wexner SD, Audisio RA. Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Eur J Surg Oncol. 2018 Nov;44(11):1685-1702. doi: 10.1016/j.ejso.2018.08.003. Epub 2018 Aug 15. Review.
  26. Omarini C, Filieri ME, Bettelli S, Manfredini S, Kaleci S, Caprera C, Nasso C, Barbolini M, Guaitoli G, Moscetti L, Maiorana A, Conte PF, Cascinu S, Piacentini F. Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. Biomed Res Int. 2018 Jul 24;2018:3756981. doi: 10.1155/2018/3756981. eCollection 2018.
  27. Cortesi L, Canossi B, Battista R, Pecchi A, Drago A, Dal Molin C, Toss A, De Matteis E, Marchi I, Torricelli P, Cascinu S. Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? Int J Cancer. 2019 Mar 1;144(5):1001-1009. doi: 10.1002/ijc.31794. Epub 2018 Oct 4.
  28. Omarini C, Bettelli S, Caprera C, Manfredini S, Caggia F, Guaitoli G, Moscetti L, Toss A, Cortesi L, Kaleci S, Maiorana A, Cascinu S, Conte PF, Piacentini F. Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. Cancer Biol Ther. 2018;19(10):879-886. doi:
  29. Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. Pancreas. 2018 Jul;47(6):759-771.
  30. Coccolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S, Fugazzola P, Tomasoni M, Glehen O, Catena F, Yonemura Y, Ansaloni L. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018 Mar; 51:120-127.
  31. Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, Bertolini F, Barbieri F, Cascinu S.Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. Crit Rev Oncol Hematol. 2018 Mar;123:149-161.
  32. Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2017 Nov 1;28(11)
  33. Gelsomino F, Bertolini F, Luppi G, Spallanzani A, Pettorelli E, Reggiani Bonetti L, Meduri B, Manco G, Conte P, Cascinu S. A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). Clin Colorectal Cancer 2017;
  34. Berardi R, Torniai M, Pusceddu S, Spada F, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, De Braud F, Falconi M, Cascinu S. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. Cancer Med. 2017 Jul;6(7):1493-1499.
  35. Demurtas L, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. Br J Cancer. 2017 Jul 25;117(3):315-321.
  36. Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G, Tortora R. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Target Oncol. 2017 Dec;12(6):795-803.
  37. Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators  Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. Eur J Cancer. 2017 Sep;83:106-115.
  38. Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. J Gastroenterol Hepatol. 2017 Sep 29.
  39. Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassineti GL, Scartozzi M. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. Eur J Cancer. 2017 Nov; 86:106-114.
  40. Grandi G, Toss A, Cagnacci A, Marcheselli L, Pavesi S, Facchinetti F, Cascinu S, Cortesi L. Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History. Clin Breast Cancer. 2018 Feb;18(1):e15-e24.
  41. Ponti G, Manfredini M, Greco S, Pellacani G, Depenni R, Tomasi A, Maccaferri M, Cascinu S. BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival. Anticancer Res. 2017 Dec;37(12):7043-7048.
  42. Salati M, Di Emidio K, Tarantino V, Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO Open. 2017 Jul 19;2(3):e000206.
  43. Van Laethem J-L, Riess H, Jassem J, et al. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted Oncology 2017; 12: 97–109
  44. Toss A, Venturelli M, Peterle C, Piacentini F, Cascinu S, Cortesi L. Molecular biomarkers for prediction of targeted therapy response in metastatic breast cancer: Trick or treat? International Journal of Molecular Sciences [Internet] 2017; 18.
  45. Toss A, Grandi G, Cagnacci A, et al. The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation. Oncotarget 2017; 8: 9144–54
  46. Silvestris N, Brunetti O, Vasile E, et al. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology 2017; 111: 152–65
  47. Petrelli F, Inno A, Barni S, et al. Borderline resectable pancreatic cancer: More than an anatomical concept. Digestive and Liver Disease 2017; 49: 223–6
  48. Orsi G, Barbolini M, Ficarra G, et al. GD2 expression in breast cancer. Oncotarget 2017; 8: 31592–600
  49. Omarini C, Guaitoli G, Noventa S, et al. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. European Journal of Surgical Oncology 2017; 43: 613–8
  50. Omarini C, Filieri ME, Depenni R, Grizzi G, Cascinu S, Piacentini F. Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. Breast Journal [Internet] 2017;
  51. Maur M, Omarini C, Piacentini F, Fontana A, Pettorelli E, Cascinu S. Metronomic capecitabine effectively blocks leptomeningeal carcinomatosis from breast cancer: A case report and literature review. American Journal of Case Reports 2017; 18: 208–11
  52. Laquente B, Lopez-Martin J, Richards D, et al. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer [Internet] 2017; 17
  53. Giampieri R, Restivo A, Pusceddu V, et al. The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical Colorectal Cancer 2017; 16: 38–43
  54. Giampieri R, Prete MD, Prochilo T, et al. Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. Scientific Reports [Internet] 2017; 7
  55. Giampieri R, Maccaroni E, Mandolesi A, et al. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer 2017; 20: 156–63
  56. Gardini AC, Foca F, Scartozzi M, et al. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study. Scientific Reports [Internet] 2017; 7
  57. Cascinu S. Anal cancer: from an orphan disease to a curable malignancy? The Lancet Oncology 2017; 18: 415–6
  58. Berardi R, Santoni M, Newsom-Davis T, et al. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget 2017; 8: 23871–9
  59. Andrikou K, Peterle C, Pipitone S, Salati M, Cascinu S. Emerging antibodies for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs 2017; 22: 39–51
  60. Zagonel V, Torta R, Franciosi V, et al. Early integration of palliative care in oncology practice: Results of the Italian Association of Medical Oncology (AIOM) survey. Journal of Cancer 2016; 7: 1968–78
  61. Silvestris N, Longo V, Cellini F, et al. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology 2016; 98: 309–24
  62. Scartozzi M, Vincent L, Chiron M, Cascinu S. Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). Targeted Oncology 2016; 11: 489–500
  63. Santoni M, Scarpelli M, Mazzucchelli R, et al. Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology 2016; 69: 186–90
  64. Santini D, Santoni M, Conti A, et al. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget 2016; 7: 33381–90
  65. Rossana B, Silvia R, Mariangela T, et al. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review. Critical Reviews in Oncology/Hematology 2016; 98: 264–74
  66. Price T, Kim TW, Li J, et al. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. European Journal of Cancer 2016; 68: 51–9
  67. Pistelli M, Ballatore Z, Santinelli A, et al. Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. Oncology Reports 2016; 36: 755–62
  68. Moretti A, Ghidini M, De Angelis C, et al. What medical oncologist residents think about the Italian speciality schools: A survey of the Italian Association of Medical Oncology (AIOM) on educational, clinical and research activities. PLoS ONE [Internet] 2016;
  69. Longo V, Brunetti O, Gnoni A, et al. Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget 2016; 7: 58649–58
  70. Iacovelli R, Nolè F, Verri E, et al. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Targeted Oncology 2016; 11: 143–8
  71. Guerra F, Marchesini M, Contadini D, et al. Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. Supportive Care in Cancer 2016; 24: 3139–45
  72. Giampieri R, Salvatore L, Del Prete M, et al. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. Scientific Reports [Internet] 2016; 6
  73. Giampieri R, Caporale M, Pietrantonio F, et al. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? Critical Reviews in Oncology/Hematology 2016; 100: 99–106
  74. Gelsomino F, Barbolini M, Spallanzani A, Pugliese G, Cascinu S. The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treatment Reviews 2016; 51: 19–26
  75. Faloppi L, Del Prete M, Casadei Gardini A, et al. The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Scientific Reports [Internet] 2016; 6
  76. Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? European Journal of Surgical Oncology 2016; 42: 1533–9
  77. Conteduca V, Santoni M, Medri M, et al. Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. Clinical Genitourinary Cancer 2016; 14: 426–31
  78. Casadei Gardini A, Scarpi E, Marisi G, et al. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group. Oncotarget 2016; 7: 15243–51
  79. Casadei Gardini A, Marisi G, Faloppi L, et al. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study. Oncotarget 2016; 7: 27988–99
  80. Bianconi M, Faloppi L, Loretelli C, et al. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Oncotarget 2016; 7: 37599–607
  81. Berardi R, Torniai M, Savini A, Rinaldi S, Cascinu S. Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? World Journal of Clinical Oncology 2016; 7: 131–4
  82. Berardi R, Santoni M, Rinaldi S, et al. Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials. PLoS ONE [Internet] 2016; 11
  83. Berardi R, Rinaldi S, Santoni M, et al. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget 2016; 7: 26916–24
  84. Berardi R, Rinaldi S, Caramanti M, et al. Hyponatremia in cancer patients: Time for a new approach. Critical Reviews in Oncology/Hematology 2016; 102: 15–25
  85. Berardi R, Morgese F, Santinelli A, et al. Hormonal receptors in lung adenocarcinoma: Expression and difference in outcome by sex. Oncotarget 2016; 7: 82648–57
  86. Berardi R, Fiordoliva I, De Lisa M, et al. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma. Tumori 2016; 102: 190–5
  87. Bandieri E, Romero M, Ripamonti CI, et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. Journal of Clinical Oncology 2016; 34: 436–42
  88. Baili P, Di Salvo F, de Lorenzo F, et al. Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study. Supportive Care in Cancer 2016; 24: 2225–33
  89. Silvestris N, Scartozzi M, Graziano G, et al. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis. Expert Opinion on Biological Therapy 2015; 15: 155–62
  90. Scartozzi M, Giampieri R, Aprile G, et al. The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. Expert Review of Molecular Diagnostics 2015; 15: 979–87
  91. Santoni M, Massari F, Iacovelli R, et al. Inside the 2015 ASCO Genitourinary Cancers Symposium. Future Oncology 2015; 11: 1859–62
  92. Santoni M, Massari F, Del Re M, et al. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. Expert Opinion on Investigational Drugs 2015; 24: 809–24
  93. Santoni M, Massari F, Cascinu S. Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. Cellular and Molecular Immunology 2015; 12: 122–4
  94. Santoni M, Crabb SJ, Conti A, et al. Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer. Clinical Genitourinary Cancer 2015; 13: 244–9
  95. Santoni M, Conti A, Procopio G, et al. Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? Journal of Experimental and Clinical Cancer Research [Internet] 2015; 34
  96. Santoni M, Conti A, Porta C, et al. Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology [Internet] 2015;
  97. Santoni M, Conti A, Partelli S, et al. Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology 2015; 22: 2094–100
  98. Santoni M, Conti A, Massari F, et al. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. International Journal of Cancer 2015; 136: 1–10
  99. Santoni M, Conti A, Andrikou K, et al. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology 2015; 96: 206–19
  100. Santoni M, Cascinu S, Mills CD. Altering macrophage polarization in the tumor environment: The role of response gene to complement 32. Cellular and Molecular Immunology 2015; 12: 783–4
  101. Santoni M, Buti S, Conti A, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology 2015; 10: 517–22
  102. Santoni M, Andrikou K, Sotte V, et al. Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. Cancer Treatment Reviews 2015; 41: 569–76
  103. Rossi L, Santoni M, Crabb SJ, et al. High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. Annals of Surgical Oncology 2015; 22: 1377–84
  104. Rihawi K, Giampieri R, Scartozzi M, et al. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opinion on Investigational Drugs 2015; 24: 1185–98
  105. Piva F, Santoni M, Matrana MR, et al. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics 2015; 15: 1201–10
  106. Piva F, Giulietti M, Occhipinti G, et al. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma. Oncotarget 2015; 6: 32161–8
  107. Pistelli M, De Lisa M, Ballatore Z, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer [Internet] 2015; 15
  108. Pantano F, Santoni M, Procopio G, et al. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? PLoS ONE [Internet] 2015; 10
  109. Morgese F, Berardi R, Sampaolesi C, et al. Gender differences and outcome of melanoma patients. Journal of Translational Medicine 2015; 1–1
  110. Minardi D, Lucarini G, Santoni M, et al. Survival in patients with clear cell renal cell carcinoma is predicted by HIF-1a expression. Anticancer Research 2015; 35: 433–8
  111. Massari F, Santoni M, Ciccarese C, et al. PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treatment Reviews 2015; 41: 114–21
  112. Massari F, Santoni M, Ciccarese C, et al. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Critical Reviews in Oncology/Hematology 2015; 96: 81–90
  113. Massari F, Ciccarese C, Santoni M, et al. Metabolic alterations in renal cell carcinoma. Cancer Treatment Reviews 2015; 41: 767–76
  114. Massari F, Ciccarese C, Santoni M, et al. The route to personalized medicine in bladder cancer: where do we stand? Targeted Oncology 2015; 10: 325–36
  115. Maccaroni E, Bracci R, Giampieri R, et al. Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? Oncotarget 2015; 6: 38737–48
  116. Iacovelli R, Santoni M, Verzoni E, et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clinical Genitourinary Cancer 2015; 13: 137–41
  117. Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology 2015; 15: 8–12
  118. Giampieri R, Scartozzi M, Del Prete M, et al. Prognostic Value for Incidental Antihypertensive Therapy With ß-Blockers in Metastatic Colorectal Cancer. Medicine 2015; 94: e719
  119. Giampieri R, Mandolesi A, Abouelkhair KM, et al. Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine [Internet] 2015;
  120. Giampieri R, Cascinu S. Maintenance therapy for metastatic colorectal cancer. The Lancet Oncology 2015; 16: 1281–2
  121. Faloppi L, Bianconi M, Giampieri R, et al. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget 2015; 6: 35087–94
  122. Del Prete M, Giampieri R, Loupakis F, et al. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. Oncotarget 2015; 6: 33982–92
  123. Del Prete M, Giampieri R, Faloppi L, et al. Panitumumab for the treatment of metastatic colorectal cancer: A review. Immunotherapy 2015; 7: 721–38
  124. de Braud F, Cascinu S, Spitaleri G, et al. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. Annals of Oncology 2015; 26: 2341–6
  125. Ciccarese C, Massari F, Santoni M, et al. New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews 2015; 41: 614–22
  126. Catania C, Maur M, Berardi R, et al. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: Dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adhesion and Migration 2015; 9: 14–21
  127. Casadei Gardini A, Marisi G, Scarpi E, et al. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy 2015; 16: 2719–25
  128. Buti S, Ciccarese C, Zanoni D, et al. Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: Where do we stand? Future Oncology 2015; 11: 107–19
  129. Brunetti O, Russo A, Scarpa A, et al. Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? Oncotarget 2015; 6: 23323–41
  130. Bodoky G, Scheulen ME, Rivera F, et al. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). Journal of Gastrointestinal Cancer 2015; 46: 109–17
  131. Bittoni A, Mandolesi A, Andrikou K, et al. HER family receptor expression and prognosis in pancreatic cancer. International Journal of Biological Markers 2015; 30: e327–32
  132. Bittoni A, Del Prete M, Scartozzi M, et al. Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. SpringerPlus 2015; 4: 1–6
  133. Berardi R, Caramanti M, Castagnani M, et al. Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Supportive Care in Cancer 2015; 23: 3095–101
  134. Berardi R, Brunelli A, Pagliaretta S, et al. Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. Oncotarget 2015; 6: 19305–15
  135. Argilés G, Saunders MP, Rivera F, et al. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. European Journal of Cancer 2015; 51: 942–9
  136. Aprile G, Leone F, Giampieri R, et al. Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology. OncoTargets and Therapy 2015; 8: 1149–56
  137. Andrikou K, Santoni M, Piva F, et al. Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses. Future Oncology 2015; 11: 1037–45
  138. Amantini C, Morelli MB, Santoni M, et al. Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience 2015; 2: 395–409
  139. Silvestris N, Vincenzi B, Brunetti AE, et al. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics 2014; 15: 1701–15
  140. Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study. International Journal of Cancer 2014; 135: 1247–56
  141. Santoni M, Scarpelli M, Mazzucchelli R, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. Journal of biological regulators and homeostatic agents 2014; 28: 555–63
  142. Santoni M, Santini D, Massari F, et al. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: Suggestions from bench to bedside. Cancer and Metastasis Reviews 2014; 33: 321–31
  143. Santoni M, Pantano F, Amantini C, et al. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochimica et Biophysica Acta - Reviews on Cancer 2014; 1845: 221–31
  144. Santoni M, Conti A, De Giorgi U, et al. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. International Journal of Cancer 2014; 135: 763–73
  145. Santoni M, Conti A, Burattini L, et al. Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. Biochimica et Biophysica Acta - Reviews on Cancer 2014; 1846: 630–7
  146. Santoni M, Bracarda S, Nabissi M, et al. CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. BioMed Research International [Internet] 2014;
  147. Santoni M, Berardi R, Amantini C, et al. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. International Journal of Cancer 2014; 134: 2772–7
  148. Santini D, Pantano F, Riccardi F, et al. Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey. PLoS ONE [Internet] 2014;
  149. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology 2014; 15: 569–79
  150. Popescu RA, Schäfer R, Califano R, et al. The current and future role of the medical oncologist in the professional care for cancer patients: A position paper by the European Society for Medical Oncology (ESMO). Annals of Oncology 2014; 25: 9–15
  151. Pistelli M, Caramanti M, Biscotti T, et al. Androgen receptor expression in early triple-negative breast cancer: Clinical significance and prognostic associations. Cancers 2014; 6: 1351–62
  152. Panzuto F, Rinzivillo M, Fave GD, et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 2014; 19: 966–74
  153. Panzuto F, Merola E, Rinzivillo M, et al. Advanced digestive neuroendocrine tumors: Metastatic pattern is an independent factor affecting clinical outcome. Pancreas 2014; 43: 212–8
  154. Iacovelli R, Alesini D, Palazzo A, et al. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treatment Reviews 2014; 40: 271–5
  155. Guida FM, Santoni M, Conti A, et al. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology 2014; 92: 208–17
  156. Giampieri R, Scartozzi M, Del Prete M, et al. The ‘angiogenetic ladder’, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treatment Reviews 2014; 40: 934–41
  157. Giampieri R, Aprile G, Del Prete M, et al. Beyond RAS: The role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients. Current Drug Targets 2014; 15: 1225–30
  158. Fontanella C, Aprile G, Scartozzi M, Lederer B, Cascinu S, Von Minckwitz G. Perspectives from American Society of Clinical Oncology: Translational and clinical research highlights in breast and colorectal cancers. Future Oncology 2014; 10: 1901–6
  159. Faloppi L, Scartozzi M, Bianconi M, et al. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: Implications for clinical management. BMC Cancer [Internet] 2014;
  160. D’Anzeo M, Faloppi L, Scartozzi M, et al. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. Molecules 2014; 19: 6393–406
  161. Cascinu S, Berardi R, Sobrero A, et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease 2014; 46: 182–6
  162. Berardi R, De Lisa M, Pagliaretta S, et al. Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treatment Reviews 2014; 40: 495–506
  163. Berardi R, Caramanti M, Fiordoliva I, et al. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. Supportive Care in Cancer 2014; 23: 621–6
  164. Scartozzi M, Giampieri R, Loretelli C, et al. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics 2013; 14: 1991–8
  165. Scartozzi M, Bianconi M, Faloppi L, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. British Journal of Cancer 2013; 108: 1126–32
  166. Santoni M, Scoccianti S, Lolli I, et al. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Journal of Neuro-Oncology 2013; 113: 397–40
  167. Santoni M, Rizzo M, Burattini L, Berardi R, Cartenì G, Cascinu S. Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming? Current Cancer Drug Targets 2013; 13: 313–25
  168. Santoni M, Massari F, Amantini C, et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy 2013; 62: 1757–68
  169. Santoni M, De Giorgi U, Iacovelli R, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. British Journal of Cancer 2013; 109: 1755–9
  170. Santoni M, Burattini L, Nabissi M, et al. Essential role of Gli proteins in glioblastoma multiforme. Current Protein and Peptide Science 2013; 14: 133–40
  171. Santoni M, Amantini C, Morelli MB, et al. Pazopanib and sunitinib trigger autophagic and non-Autophagic death of bladder tumour cells. British Journal of Cancer 2013; 109: 1040–50
  172. Ramalingam S, Crawford J, Chang A, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Annals of Oncology 2013; 24: 2875–80
  173. Pistelli M, Pagliacci A, Battelli N, et al. Prognostic factors in early-stage triple-negative breast cancer: Lessons and limits from clinical practice. Anticancer Research 2013; 33: 2737–42
  174. Negri FV, Azzoni C, Bottarelli L, et al. Thymidylate synthase, topoisomerase-1 and microsatellite instability: Relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Research 2013; 33: 4611–7
  175. Maison-Blanche P, Vermorken JB, Goksel T, et al. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. Journal of Cardiovascular Pharmacology 2013; 61: 495–504
  176. Leone F, Artale S, Marino D, et al. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: The MetaPan study. Cancer 2013; 119: 3429–35
  177. Iacovelli R, Altavilla A, Procopio G, et al. Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials. Prostate Cancer and Prostatic Diseases 2013; 16: 323–7
  178. Giampieri R, Scartozzi M, Loretelli C, et al. Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients. PLoS ONE [Internet] 2013; 8
  179. Giampieri R, Scartozzi M, Del Prete M, et al. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Critical Reviews in Oncology/Hematology 2013; 88: 272–8
  180. Faloppi L, Andrikou K, Cascinu S. Cetuximab: Still an option in the treatment of pancreatic cancer? Expert Opinion on Biological Therapy 2013; 13: 791–80
  181. Bracci R, Maccaroni E, Cascinu S. Transient sunitinib resistance in gastrointestinal stromal tumors. New England Journal of Medicine 2013; 368: 2042–3
  182. Bittoni A, Scartozzi M, Giampieri R, et al. The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? Critical Reviews in Oncology/Hematology 2013; 85: 332–41
  183. Bittoni A, Scartozzi M, Giampieri R, et al. Clinical evidence for three distinct gastric cancer subtypes: Time for a new approach. PLoS ONE [Internet] 2013; 8 Berardi R, Santoni M, Morgese F, et al. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. OncoTargets and Therapy 2013; 6: 563–76
  184. Berardi R, Nacciarriti D, Tamburrano T, et al. Compliance with breast and cervical cancer screening programs in women: Results from a population-based study. Tumori 2013; 99: 565–71
  185. Berardi R, Mocchegiani F, Pierantoni C, et al. Resected biliary tract cancers: A novel clinical-pathological score correlates with global outcome. Digestive and Liver Disease 2013; 45: 70–4
  186. Berardi R, Caramanti M, Savini A, et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. Critical Reviews in Oncology/Hematology 2013; 88: 75–86
  187. Ajani JA, Buyse M, Lichinitser M, et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. European Journal of Cancer 2013; 49: 3616–24
  188. Zaniboni A, Aitini E, Barni S, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: A GISCAD multicenter phase II study. Cancer Chemotherapy and Pharmacology 2012; 69: 1641–5
  189. Scartozzi M, Loretelli C, Galizia E, et al. Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PLoS ONE [Internet] 2012; 7
  190. Scartozzi M, Loretelli C, Berardi R, et al. Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. Digestive and Liver Disease 2012; 44: 74–9
  191. Scartozzi M, Giampieri R, Maccaroni E, et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Annals of Oncology 2012; 23: 1706–12
  192. Scartozzi M, Giampieri R, MacCaroni E, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. British Journal of Cancer 2012; 106: 799–804
  193. Scartozzi M, Faloppi L, Bianconi M, et al. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: Implications for clinical management. PLoS ONE [Internet] 2012; 7
  194. Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? Annals of Oncology 2012; 23: 2313–8
  195. Santini D, Tampellini M, Vincenzi B, et al. Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study. Annals of Oncology 2012; 23: 2072–7
  196. Lutz MP, Zalcberg JR, Ducreux M, et al. Highlights of the EORTC st. gallen international expert consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer. European Journal of Cancer 2012; 48: 2941–53
  197. Gasparini G, Torino F, Ueno T, et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012; 15: 141–50
  198. Berardi R, Maccaroni E, Mandolesi A, et al. Nuclear factor-?B predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. Digestive and Liver Disease 2012; 44: 617–22
  199. Belvederesi L, Bianchi F, Loretelli C, Bracci R, Cascinu S, Cellerino R. Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. Familial Cancer 2012; 11: 675–80
  200. Van Cutsem E, Köhne C-H, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011; 29: 2011–9
  201. Scartozzi M, Siquini W, Galizia E, et al. The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. Digestive and Liver Disease 2011; 43: 194–8
  202. Scartozzi M, Mandolesi A, Giampieri R, et al. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 2011; 16: 53–60
  203. Scartozzi M, Maccaroni E, Giampieri R, et al. 5-Fluorouracil pharmacogenomics: Still rocking after all these years? Pharmacogenomics 2011; 12: 251–65
  204. Scartozzi M, Loretelli C, Bearzi I, et al. Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. Annals of Oncology 2011; 22: 897–902
  205. Scartozzi M, Bianconi M, Maccaroni E, et al. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Discovery medicine 2011; 11: 144–5
  206. Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer 2011; 104: 1786–90
  207. Faloppi L, Scartozzi M, Maccaroni E, et al. Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options. Cancer Treatment Reviews 2011; 37: 169–77
  208. Cascinu S, Galizia E, Labianca R, et al. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: A randomized phase II trial. Cancer Chemotherapy and Pharmacology 2011; 68: 37–4
  209. Scartozzi M, Mazzanti P, Giampieri R, et al. Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? Lung Cancer 2010; 68: 433–7
  210. Scartozzi M, Mandolesi A, Giampieri R, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer 2010; 127: 1941–7
  211. Scartozzi M, Bianconi M, MacCaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mab targeted against IGFR1 for the treatment of cancer. Current Opinion in Molecular Therapeutics 2010; 12: 361–71
  212. Loupakis F, Masi G, Fornaro L, et al. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology 2010; 66: 559–66
  213. Cascinu S, Falconi M, Valentini V, Jelic S. Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010; 21: v55–8
  214. Bittoni A, Maccaroni E, Scartozzi M, Berardi R, Cascinu S. Chemotherapy for locally advanced and metastatic gastric cancer: State of the art and future perspectives. European Review for Medical and Pharmacological Sciences 2010; 14: 309–14
  215. Tiseo M, Gridelli C, Cascinu S, et al. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer 2009; 64: 199–206
  216. Siena S, Crinó L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: A multicenter phase II study. Annals of Oncology 2009; 21: 655–61
  217. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annals of Oncology 2009; 20: 227–30
  218. Scartozzi M, Bittoni A, Pistelli M, et al. Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. Cancer Treatment Reviews 2009; 35: 451–62
  219. Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer [Internet] 2009;
  220. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal of Cancer 2009; 101: 1261–8
  221. Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009; 115: 1544–54
  222. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology 2009; 27: 2622–9
  223. Gagliardi C, Vespa A, Papa R, Mariotti C, Cascinu S, Rossini S. Social support networks and depression of women suffering from early-stage breast cancer: A case control study. Journal of Psychosocial Oncology 2009; 27: 216–29
  224. Celio L, Sternberg CN, Labianca R, et al. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: A multi-institutional phase II study. Annals of Oncology 2009; 20: 1062–7
  225. Cascinu S, Jelic S. Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2009; 20: iv37-iv40
  226. Berardi R, Verdecchia L, Paolo MDP, et al. Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. A literature review. Critical Reviews in Oncology/Hematology 2009; 69: 223–36
  227. Berardi R, Mantello G, Scartozzi M, et al. Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinical-Pathologic Score Correlates With Global Outcome. International Journal of Radiation Oncology Biology Physics 2009; 75: 1437–43
  228. Van Cutsem E, Van de Velde C, Roth A, et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group. European Journal of Cancer 2008; 44: 182–94
  229. Reni M, Berardi R, Mambrini A, et al. A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology 2008; 62: 673–8
  230. Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Bianconi M, Cascinu S. Pancreatic cancer: Progress in cancer therapy. Critical Reviews in Oncology/Hematology 2008; 67: 27–38
  231. Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. British Journal of Cancer 2008; 98: 143–7
  232. Mercadante S, Roila F, Berretto O, et al. Prevalence and treatment of cancer pain in Italian oncological wards centres: A cross-sectional survey. Supportive Care in Cancer 2008; 16: 1203–11
  233. Galizia E, Scartozzi M, Berardi R, Pistelli M, Bittoni A, Cascinu S. Adjuvant treatment for radically resected gastric cancer patients: The vexata quaestio. Advances in Gastrointestinal Cancers 2008; 6: 2–7
  234. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC. Journal of the National Cancer Institute 2008; 100: 388–98
  235. Cascinu S, Berardi R, Salvagni S, et al. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. British Journal of Cancer 2008; 98: 71–6
  236. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. The Lancet Oncology 2008; 9: 39–44
  237. Braconi C, Bracci R, Bearzi I, et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Annals of Oncology 2008; 19: 1293–8
  238. Braconi C, Bracci R, Bearzi I, et al. KIT and PDGFRa mutations in 104 patients with gastrointestinal stromal tumors (GISTs): A population-based study. Annals of Oncology 2008; 19: 706–10
  239. Berardi R, Giampieri R, Di Pietro PM, Scartozzi M, Cascinu S. Molecular factors in the treatment of the B stages of colon cancer. Cancer and Chemotherapy Reviews 2008; 3: 97–117
  240. Verslype C, Van Cutsem E, Dicato M, et al. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Annals of Oncology 2007; 18: vii1-vii10
  241. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. Journal of Clinical Oncology 2007; 25: 3930–5
  242. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Pierantoni C, Cascinu S. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: Optimising EGFR-targeted treatment options. British Journal of Cancer 2007; 97: 92–7
  243. Scartozzi M, Galizia E, Verdecchia L, et al. Chemotherapy for advanced gastric cancer: Across the years for a standard of care. Expert Opinion on Pharmacotherapy 2007; 8: 797–808
  244. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. Journal of Clinical Oncology 2007; 25: 3238–45
  245. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Annals of Oncology 2007; 18: 510–7
  246. Mandalà M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Annals of Oncology 2007; 18: 1660–5
  247. Grillo-Ruggieri F, Mantello G, Berardi R, et al. Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy. Diseases of the Colon and Rectum 2007; 50: 1594–603
  248. Cazzaniga ME, Dogliotti L, Cascinu S, et al. Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: Results from a prospective, multicenter study. Oncology 2007; 71: 374–81
  249. Cascinu S, Scartozzi M, Carbonari G, et al. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. American Journal of Clinical Oncology: Cancer Clinical Trials 2007; 30: 526–30
  250. Cascinu S, Scartozzi M, Barone C, et al. Response: Re: Adjuvant treatment of high-risk, radically resected rastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial [5]. Journal of the National Cancer Institute 2007; 99: 1346–7
  251. Cascinu S, Labianca R, Barone C, et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. Journal of the National Cancer Institute 2007; 99: 601–7
  252. Berardi R, Scartozzi M, Freddari F, et al. ‘Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review’ [Cancer Treatment Reviews 32(5) (2006) 333-347]
  253. Scartozzi M, Pierantoni C, Berardi R, Squadroni M, Cascinu S. Anti-EGFR strategies as an incremantal step for the treatment of colorectal cancer patients: Moving from scientific evidence to clinical practice. Expert Opinion on Therapeutic Targets 2006; 10: 281–7
  254. Scartozzi M, Galizia E, Verdecchia L, et al. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. British Journal of Cancer 2006; 95: 445–9
  255. Scartozzi M, Franciosi V, Campanini N, et al. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006; 53: 103–9
  256. Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. Journal of Clinical Oncology 2006; 24: 1883–91
  257. Rossana B, Mario S, Federica F, et al. Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review. Cancer Treatment Reviews 2006; 32: 333–47
  258. Pergolizzi S, Adamo V, Russi E, et al. Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. International Journal of Radiation Oncology Biology Physics 2006; 65: 25–32
  259. Berardi R, Braconi C, Mantello G, et al. Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Annals of Oncology 2006; 17: 1661–4
  260. Battelli N, Massacesi C, Braconi C, et al. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. American Journal of Clinical Oncology: Cancer Clinical Trials 2006; 29: 380–4
  261. Scartozzi M, Sobrero A, Gasparini G, et al. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. Oncology 2005; 68: 212–6
  262. Scartozzi M, Galizia E, Graziano F, et al. Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. British Journal of Cancer 2005; 92: 1051–4
  263. Scartozzi M, Berardi R, Pierantoni C, Cascinu S. Pre-operative treatment modalities in gastric cancer patients. Annals of Oncology 2005; 16: iv106-iv109
  264. Ruzzo A, Graziano F, Pizzagalli F, et al. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Annals of Oncology 2005; 16: 887–92
  265. Mantello G, Berardi R, Cardinali M, et al. Feasibility of preoperative chemoradiation in rectal cancer patients aged 70 and older. Journal of Experimental and Clinical Cancer Research 2005; 24: 541–6
  266. Kawakami K, Graziano F, Watanabe G, et al. Prognostic role of Thymidylate Synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clinical Cancer Research 2005; 11: 3778–83
  267. Graziano F, Ruzzo A, Santini D, et al. Prognostic role of interleukin-1ß gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. Journal of Clinical Oncology 2005; 23: 2339–45
  268. Catalano T, Curia MC, Aceto G, et al. Mutations in the p753 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. Oncology Reports 2005; 14: 625–31
  269. Berardi R, Verdecchia L, Scartozzi M, Cascinu S. New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: Apart from therapeutical protocols. Journal of the Pancreas 2005; 6: 118–21
  270. Berardi R, Brunelli A, Tamburrano T, et al. Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer 2005; 49: 371–6
  271. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S. Molecular biology of sporadic gastric cancer: Prognostic indicators and novel therapeutic approaches. Cancer Treatment Reviews 2004; 30: 451–9
  272. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. Journal of Clinical Oncology 2004; 22: 4720–6
  273. Graziano F, Mandolesi A, Ruzzo A, et al. Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. Tumor Biology 2004; 25: 106–10
  274. Graziano F, Kawakami K, Watanabe G, et al. Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. International Journal of Cancer 2004; 112: 1010–4
  275. Graziano F, Arduini F, Ruzzo A, et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: Implications for treatment with demethylating drugs. Annals of Oncology 2004; 15: 489–92
  276. Graziano F, Arduini F, Ruzzo A, et al. Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer. Clinical Cancer Research 2004; 10: 2784–9
  277. Galizia E, Berardi R, Scartozzi M, Cascinu S. A cost-benefit analysis of chemotherapy for gastric cancer. Expert Opinion on Pharmacotherapy 2004; 5: 2109–14
  278. De Braud F, Cascinu S, Gatta G. Cancer of pancreas. Critical Reviews in Oncology/Hematology 2004; 50: 147–55
  279. Cascinu S, Scartozzi M, Labianca R, et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer 2004; 90: 1521–5
  280. Berardi R, Scartozzi M, Romagnoli E, Antognoli S, Cascinu S. Gastric cancer treatment: A systematic review. Oncology Reports 2004; 11: 911–6
  281. Roila F, Ballatori E, Patoia L, et al. Adjuvant systemic therapies in women with breast cancer: An audit of clinical practice in Italy. Annals of Oncology 2003; 14: 843–8
  282. Nizzoli R, Bozzetti C, Crafa P, et al. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagnostic Cytopathology 2003; 28: 142–6
  283. Morabito A, Filippelli G, Palmeri S, et al. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: A phase I-II study. Breast Cancer Research and Treatment 2003; 78: 29–36
  284. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology 2003; 14: 29–35
  285. Graziano F, Santini D, Testa E, et al. A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. British Journal of Cancer 2003; 89: 1428–32
  286. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Duke’s B colorectal cancer patients: How much evidence is enough? Annals of Oncology 2003; 14: 1026–38
  287. Gaeta M, Blandino A, Pergolizzi S, et al. Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: A radiological, histological, and immunohistochemical study. Lung Cancer 2003; 42: 319–26
  288. Franciosi V, Barbieri R, Aitini E, et al. Gemcitabine and oxaliplatin: A safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 2003; 41: 101–6
  289. Falconi M, Mantovani W, Bettini R, et al. Carcinoma of pancreatic body and tail: Are there improvements in diagnosis and treatment modalities over the past decade? Digestive and Liver Disease 2003; 35: 421–7
  290. Cocconi G, Franciosi V, Dodero A, et al. P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study. American Journal of Clinical Oncology: Cancer Clinical Trials 2003; 26: 535–42
  291. Cascinu S, Labianca R, Catalano V, et al. Weekly gemcitabine and cisplatin chemotherapy: A well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology 2003; 14: 205–8
  292. Cascinu S, Graziano F, Catalano V, et al. Vascular endothelial growth factor and p53 expressions in liver and abdominal metastases from colon cancer. Tumor Biology 2003; 24: 77–8
  293. Cascinu S, Giordani P, Agostinelli R, et al. Pain and its treatment in hospitalized patients with metastatic cancer. Supportive Care in Cancer 2003; 11: 587–92
  294. Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M. Colorectal cancer in the adjuvant setting: Perspectives on treatment and the role of prognostic factors. Annals of Oncology 2003; 14: ii25-ii29
  295. Cascinu S, Catalano V, Piga A, et al. The Role of Levamisole in the Adjuvant Treatment of Stage III Colon Cancer Patients: A Randomized Trial of 5-Fluorouracil and Levamisole Versus 5-Fluorouracil Alone. Cancer Investigation 2003; 21: 701–7
  296. Bozzetti C, Personeni N, Nizzoli R, et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 2003; 99: 310–5
  297. Berardi R, Piga A, Pulita F, et al. Effective prevention of 5-fluorouracil-induced superficial phlebitis by ketoprofen lysine salt gel [4]. American Journal of Medicine 2003; 115: 415–7
  298. Merendino RA, Ruello A, Cascinu S, et al. Influence of 5-fluorouracil and folinic acid on interleukin-18 production in colorectal cancer patients. International Journal of Biological Markers 2002; 17: 63–6
  299. Lippe P, Silva RR, Giuliodori L, et al. Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients. Anticancer Research 2002; 22: 1053–9
  300. Humar B, Graziano F, Cascinu S, et al. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 2002; 21: 8192–5
  301. Cascinu S, Graziano F, Ferraù F, et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Annals of Oncology 2002; 13: 716–20
  302. Cascinu S, Graziano F, Catalano V, et al. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. British Journal of Cancer 2002; 86: 744–9
  303. Cascinu S, Franciosi V, Salvagni S, Gasparro D, Mare M, Camisa R. Pamidronate in the treatment of bone metastases [Il pamidronato nel trattamento delle metastasi ossee]. European Journal of Oncology 2002; 7: 21–4
  304. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2002; 20: 3478–83
  305. Cascinu S, Baldelli AM, Catalano V, et al. Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen. British Journal of Cancer 2002; 86: 213–7
  306. Bozzetti C, Nizzoli R, Guazzi A, et al. Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer. Lung Cancer 2002; 35: 243–7
  307. Bozzetti C, Nizzoli R, Guazzi A, et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Annals of Oncology 2002; 13: 1398–403
  308. Aschele C, Debernardis D, Bandelloni R, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Annals of Oncology 2002; 13: 1882–92
  309. Pergolizzi S, Settineri N, Santacaterina A, et al. Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy. Annals of Oncology 2001; 12: 1091–5
  310. Maisano R, Pergolizzi S, Cascinu S. Novel therapeutic approaches to cancer patients with bone metastasis. Critical Reviews in Oncology/Hematology 2001; 40: 239–50
  311. Graziano F, Catalano V, Baldelli AM, Cascinu S. Prognostic biomarkers in resected colorectal cancer: Implications for adjuvant chemotherapy. Expert Review of Anticancer Therapy 2001; 1: 247–57
  312. Graziano F, Cascinu S, Staccioli MP, et al. Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer. BMC Cancer 2001; 1: 9
  313. Catalano V, Baldelli AM, Giordani P, Cascinu S. Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Critical Reviews in Oncology/Hematology 2001; 38: 93–104
  314. Casella G, Cacopardo E, Rovere G, Buda CA, Cascinu S, Baldini V. Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. Journal of Clinical Ultrasound 2001; 29: 354–8
  315. Cascinu S, Graziano F, Valentini M, et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy. Annals of Oncology 2001; 12: 239–44
  316. Cascinu S, Graziano F, Catalano V, et al. Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clinical and Experimental Metastasis 2001; 18: 651–5
  317. Cascinu S, Graziano F, Barni S, et al. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. British Journal of Cancer 2001; 84: 470–4
  318. Cascinu S, Del Ferro E, Ligi M, et al. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Investigation 2001; 19: 8–12
  319. Cascinu S, Catalano V, Giordani P, Baldelli AM, Agostinelli R, Catalano G. Gastrointestinal cancer refractory to chemotherapy: A role for octreotide? Chemotherapy 2001; 47: 127–33
  320. Aragona M, Panetta S, Silipigni AM, et al. Nerve growth factor receptor immunoreactivity in breast cancer patients. Cancer Investigation 2001; 19: 692–7
  321. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Annals of Oncology 2000; 11: 837–43
  322. Graziano F, Catalano V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Annals of Oncology 2000; 11: 1263–6
  323. Cascinu S, Valenti A, Amadio P, et al. Erratum: Angiosuppression and chemotherapy: Strategies for integrating them in cancer patients (The International Journal of Biological Markers (1999) 14, 4 (239-242)). International Journal of Biological Markers 2000; 15: 202
  324. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clinical Cancer Research 2000; 6: 2803–7
  325. Cascinu S, Ligi M, Del Ferro E, et al. Effects of calcium and vitamin supplementation on colon cell proliferation in colorectal cancer. Cancer Investigation 2000; 18: 411–6
  326. Cascinu S, Graziano F, Catalano V, et al. Prognostic value of S-Phase Fraction in T3N0M0 gastric cancer. Implications for adjuvant chemotherapy. Anticancer Research 2000; 20: 3839–42
  327. Cascinu S, Frontini L, Labianca R, et al. A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology 2000; 11: 1309–11
  328. Cascinu S, Catalano V, Aschele C, et al. Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Annals of Oncology 2000; 11: 1053–6
  329. Cascinu S, Bichisao E, Amadori D, et al. High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Supportive Care in Cancer 2000; 8: 65–7
  330. Lippe P, Tummarello D, Monterubbianesi MC, et al. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study. Annals of Oncology 1999; 10: 217–21
  331. Cascinu S, Valenti A, Mesiti M, Gasparini G. Angiosuppression and chemotherapy: Strategies aimed at their integration in cancer patients. International Journal of Biological Markers 1999; 14: 239–42
  332. Cascinu S, Silva RR, Labianca R, et al. A phase II study of Tomudex alternated with methotrexate, 5- fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. Annals of Oncology 1999; 10: 985–7
  333. Cascinu S, Silva RR, Barni S, et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer 1999; 80: 1595–8
  334. Cascinu S, Labianca R, Barni S, et al. Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). GI Cancer 1999; 3: 79–83
  335. Cascinu S, Graziano F, Catalano G. Chemotherapy for advanced pancreatic cancer: It may no longer be ignored. Annals of Oncology 1999; 10: 105–9
  336. Cascinu S, Giordani P, Quattrone A, et al. Intensive versus standard chemotherapy in elderly gastric cancer patients: A retrospective analysis. GI Cancer 1999; 3: 97–101
  337. Cascinu S, Giordani P, Catalano V, Agostinelli R, Catalano G. Resection-line involvement in gastric cancer patients undergoing curative resections: Implications for clinical management. Japanese Journal of Clinical Oncology 1999; 29: 291–3
  338. Cascinu S, Gasparini G, Catalano V, et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology 1999; 10: 1377–81
  339. Cascinu S, Frontini L, Comella G, et al. Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer 1999; 79: 491–4
  340. Cascinu S, Aschele C, Barni S, et al. Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clinical Cancer Research 1999; 5: 1996–9
  341. Cascinu S, Ligi M, Graziano F, et al. S-phase fraction can predict event free survival in patients with pT2- T3N0M0 colorectal carcinoma: Implications for adjuvant chemotherapy. Cancer 1998; 83: 1081–5
  342. Cascinu S, Labianca R, Graziano F, et al. Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer 1998; 78: 390–3
  343. Cascinu S, Graziano F, Del Ferro E, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998; 83: 1917–22
  344. Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anti-Cancer Drugs 1998; 9: 307–10
  345. Cascinu S, Graziano F, Alessandroni P, et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Supportive Care in Cancer 1998; 6: 139–43
  346. Cascinu S, Del Ferro E, Ligi M, et al. Cell kinetics and DNA distribution patterns determined by flow cytometry in early and advanced gastric cancer. GI Cancer 1998; 2: 197–201
  347. Cascinu S, Catalano V, Baldelli AM, et al. Locoregional treatments of unresectable liver metastases from colorectal cancer. Cancer Treatment Reviews 1998; 24: 3–14
  348. Cascinu S, Battelli N, Scartozzi M, Baldelli AM, Cellerino R. Symptomatic effects of methotrexate, 5fluorouracil and leucovorin in advanced colorectal cancer after failure of 5FU continuous infusion. GI Cancer 1998; 2: 203–6
  349. Labianca R, Cascinu S, Frontini L, et al. High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study. Annals of Oncology 1997; 8: 169–74
  350. Cascinu S, Labianca R, Alessandroni P, et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: A report from the Italian group for the study of digestive tract cancer. Journal of Clinical Oncology 1997; 15: 3313–9
  351. Cascinu S, Ficarelli R, Safi MAA, Graziano F, Catalano G, Cellerino R. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. European Journal of Cancer 1997; 33: 1699–702
  352. Cascinu S, Del Ferro E, Ligi M, et al. Lack of correlation between octreotide dose and decrease of serum insulin growth factor-I in advanced colorectal cancer patients. GI Cancer 1997; 2: 139–42
  353. Cascinu S, Del Ferro E, Ligi M, Graziano F, Catalano G. The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials 1997; 20: 477–8
  354. Cascinu S, Del Ferro E, Grianti C, et al. Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Gastroenterology 1997; 113: 767–72
  355. Cascinu S, Del Ferro E, Grianti C, et al. Measurements of cellular proliferation by 3H-thymidine-labeling index and flow cytometry in breast cancer patients. Oncology Reports 1997; 4: 539–41
  356. Cascinu S, Del Ferro E, Grianti C, Ligi M, Catalano G. S-Phase fraction and tumor aneuploidy in young patients with gastric carcinoma. GI Cancer 1997; 2: 149–52
  357. Cascinu S, Del Ferro E, Barbanti I, Ligi M, Fedeli A, Catalano G. Tumor markers in the diagnosis of malignant serous effusions. American Journal of Clinical Oncology: Cancer Clinical Trials 1997; 20: 247–50
  358. Cascinu S, Catalano V, Scartozzi M, Baldelli AM, Cellerino R. Liver metastases from colorectal cancer. Annals of Oncology 1997; 8: 393–9
  359. Cascinu S, Barni S, Labianca R, et al. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian group for the study of digestive tract cancer (GISCAD) study. Supportive Care in Cancer 1997; 5: 314–7
  360. Piga A, Cascinu S, Latini L, et al. A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. British Journal of Cancer 1996; 74: 971–4
  361. Cavaletti G, Cascinu S, Venturino P, Tedeschi M, Tredici G. Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Research 1996; 16: 3149–59
  362. Cascinu S, Wadler S. Chemo-embolization in the treatment of liver metastases from colorectal cancer. Cancer Treatment Reviews 1996; 22: 355–63
  363. Cascinu S, Valentini G, Fiorentini G, Riggio S, Catalano G. Temporary small-gauge catheter for intraperitoneal chemotherapy: Indications and feasibility. Regional Cancer Treatment 1996; 9: 44–5
  364. Cascinu S, Ferro ED, Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. American Journal of Clinical Oncology: Cancer Clinical Trials 1996; 19: 371–4
  365. Cascinu S, Del Ferro E, Ligi M, Graziano F, Castellani, Catalano G. Phase II trial of 13-cis retinoic acid plus interferon-a in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy [4]. Annals of Oncology 1996; 7: 538–9
  366. Cascinu S, Del Ferro E, Ligi M, Catalano G. A phase I trial of 5-fluorouracil, leucovorin and interferon-a2b administered by 24 h infusion in metastatic colorectal carcinoma. Anti-Cancer Drugs 1996; 7: 520–4
  367. Cascinu S, Del Ferro E, Grianti C, Ligi M, Catalano G. S-phase fraction and tumor aneuploidy in colorectal carcinoma of young patients. Cancer 1996; 78: 1857–60
  368. Cascinu S, Del Ferro E, Catalano G. Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer: A randomized study. Anti-Cancer Drugs 1996; 7: 43–7
  369. Cascinu S, Casadei V, Del Ferro E, Alessandroni P, Catalano G. Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. Supportive Care in Cancer 1996; 4: 31–3
  370. Cascinu S, Battelli N, Graziano F, et al. c-erbB-2 and common prognostic factors in breast cancer patients. Oncology Reports 1996; 3: 883–6
  371. Cascinu S, Alessandroni P, Rossi D, et al. Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology 1996; 38: 385–6
  372. Cascinu S. Management of diarrhea induced by tumors or cancer therapy. Current Opinion in Oncology 1995; 7: 325–9
  373. Cascinu S. Drug therapy in diarrheal diseases in oncology/hematology patients. Critical Reviews in Oncology and Hematology 1995; 18: 37–50
  374. Cascinu S, Latini L, Fedeli A, et al. The clinical impact of FEM regimen (5-fluorouracil, 4-epidoxorubicin and mitomycin-C) in advanced gastric cancer patients. Anticancer Research 1995; 15: 2781–3
  375. Cascinu S, Garbugli S, Catalano G. Weekly 24-hour infusion with high-dose 5-fluorouracil and 6S-leucovorin as a second-line therapy in advanced colorectal cancer resistant to a 5-fluorouracil/6S-leucovorin bolus combination. Oncology Reports 1995; 2: 377–9
  376. Cascinu S, Del Ferro E, Grianti C, Fedeli A, Catalano G. Oral escalating dose of cyclosporin A combined with 4-epidoxorubicin in advanced colorectal cancer: A phase I study. Oncology Reports 1995; 2: 1033–5
  377. Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology 1995; 52: 422–6
  378. Cascinu S, Del Ferro E, Catalano G. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. British Journal of Cancer 1995; 71: 97–101
  379. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. Journal of Clinical Oncology 1995; 13: 26–32
  380. Cascinu S, Catalano G. Have enteric infections a role in 5-fluorouracil-associated diarrhea? Supportive Care in Cancer 1995; 3: 322–3
  381. Cascinu S, Catalano G. Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. Anti-Cancer Drugs 1995; 6: 608–11
  382. Cascinu S, Catalano G, Cellerino R. Recombinant human erythropoietin in chemotherapy-associated anemia. Cancer Treatment Reviews 1995; 21: 553–64
  383. Labianca R, Giaccon G, Barni S, et al. Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-a2b and folinic acid. The ‘GISCAD’ experience. European Journal of Cancer 1994; 30: 1611–6
  384. Cascinu S, Valentini G, Fiorentini G, et al. Intraperitoneal carboplatin, etoposide and interferon alpha 2b in women with residual ovarian cancer confined to peritoneum after an intravenous cisplatin containing regimen chemotherapy. Regional Cancer Treatment 1994; 7: 47–50
  385. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. European Journal of Cancer Part B: Oral Oncology 1994; 30: 234–6
  386. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhea with octreotide: A randomized trial with placebo in patients receiving cisplatin. Oncology (Switzerland) 1994; 51: 70–3
  387. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. British Journal of Cancer 1994; 69: 392–3
  388. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. Journal of Clinical Oncology 1994; 12: 1058–62
  389. Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Carboplatin associated anemia treated with subcutaneous erythropoietin. A pilot study. Oncology Reports 1994; 1: 169–72
  390. Cascinu S, Fedeli A, Catalano G. Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. Cancer Chemotherapy and Pharmacology 1994; 34: 72–4
  391. Cascinu S, Del Ferro E, Ligi M, Sani F, Grianti C, Catalano G. Correlation among [3H]thymidine, flow cytometry and proliferating cell nuclear antigen indices in colorectal tumours. Oncology Reports 1994; 1: 1229–32
  392. Cascinu S, Isidori PP, Fedeli SL, et al. A phase 1 study of carboplatin and a-2 interferon in patients with malignant pleural effusions. Cancer Journal 1993; 6: 330–3
  393. Cascinu S, Ferro ED, Fedeli A, et al. Cytokinetic Effects of Interferon in Colorectal Cancer Tiimors: Implications in the Design of the Interferon/5-fluorouracil Combinations. Cancer Research 1993; 53: 5429–32
  394. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. British Journal of Cancer 1993; 67: 156–8
  395. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. 5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: A pilot study. Annals of Oncology 1993; 4: 83–4
  396. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial. Journal of Clinical Oncology 1993; 11: 148–51
  397. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Intensive weekly chemotherapy for advanced gastric cancer using 5- fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and granulocyte- colony stimulating factor. International Journal of Oncology 1993; 3: 535–8
  398. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Cisplatin treatment in cancer patients with hyperbilirubinemia due to secondary liver involvement. Cancer Journal 1993; 6: 151–3
  399. Cascinu S, Fedeli A, Catalano G. Breast cancer developing after therapy for Hodgkin’s disease. Clinical Oncology 1993; 5: 61–2
  400. Cascinu S, Fedelil A, Luzi Fedeli S, Catalano G. Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. Annals of Oncology 1992; 3: 489–91
  401. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination. Journal of Chemotherapy 1992; 4: 185–8
  402. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluoroacil/leucovorin combination. Journal of Chemotherapy 1992; 4: 46–9
  403. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. 5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study. Journal of Chemotherapy 1991; 3: 51–4
  404. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Treatment of metastatic renal cell carcinoma with daily high dose of alpha 2b interferon. A phase II study. Cancer Journal 1991; 4: 388–90

 

English version

Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.

Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.